The Liver Meeting: Rectify Pharma presented preclinical data supporting its hypothesis of improving the function of dysfunctional membrane proteins: ABCB4 and BSEP

blonca9
Nov 20, 2024
1 min read

CEO Rajesh Devraj describes the company's focus on membrane protein function and normalizing it with small molecules, in this case for cholestasis and cholangitis associated with liver diseases.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

The Liver Meeting: Rectify Pharma presented preclinical data supporting its hypothesis of improving the function of dysfunctional membrane proteins: ABCB4 and BSEP

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight